China Resources Pharmaceutical completes first tranche of 2025 medium term notes

China Resources Pharmaceutical Commercial Group Company Limited, a subsidiary of China Resources Pharmaceutical Group Limited, has completed the issuance of the first tranche of its Medium Term Notes 2025 in the PRC on December 15, 2025. This marks a significant step in the company's financing strategy as outlined in its December 1, 2025 announcement.

The inaugural tranche of Medium Term Notes 2025 was issued with a principal amount of RMB3 billion. These notes carry a term of 3 years, with a potential for renewal upon expiration, and offer a coupon rate of 2.19% per annum.

The proceeds generated from this issuance will be strategically utilized for the repayment of interest-bearing debt owed by CR Pharmaceutical Commercial or its various subsidiaries, aiming to optimize the group's financial structure.